Drug intelligence / Profile preview

SYP-2135

Development stage: Preclinical
Lead developer: Samyang Holdings Biopharm Group
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Injection

Overview

SYP-2135 is an investigational mRNA-based cancer vaccine being developed by Samyang Holdings Biopharm Group. It utilizes the company's proprietary SENS™ (Samyang Elucidated Nanoparticle System) delivery platform, which is designed to effectively deliver mRNA into target cells using specialized nanoparticles. As a cancer vaccine, SYP-2135 is intended to stimulate the patient's immune system to recognize and attack tumor-specific antigens. It is currently in the preclinical stage of development for the treatment of various cancers.

Beyond the preview

Go deeper on SYP-2135.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYP-2135.

Explore the full profile